Calgary, Alberta--(Newsfile Corp. - October 22, 2025) - Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in SaaS clinical division support solutions, is pleased to announce that it has completed the development and anticipates deploying its new analytics module "MetricsGuard" to Seegnal's patient tailored medication standard software. The new "MetricsGuard" is an intelligent layer that transforms how clinicians detect and respond to patient-specific risks by extending Seegnal's current logic, which currently already overrides physician bypasses in cases of drug-drug interaction alerts, when lab results, vital signs, or serum drug levels suggest a drug-to-drug-related risk, to detect and alert for single-drug-to-patient metrics-related risks. Seegnal anticipates releasing the new module in Q4, 2025, with the first two orders signed by customers.
With this new innovative module, Seegnal identifies deviations in patient metrics and generates alerts when the condition is classified as Contraindicated or as a Severe warning for a specific medication. This unique functionality analyses additional risks that might impact patient safety and should be addressed by the clinician if found true, for example: hypoglycemia & sulfonylureas, hyponatremia & diuretics, bradycardia & beta-blockers, hypocalcemia & denosumab, or a predisposing factor for toxicity such as hypokalemia or hypomagnesemia & digoxin.
By continuously analyzing patient data in real-time, Seegnal delivers actionable, personalized alerts that empower clinicians to intervene earlier, prevent harm, and ensure safer, more precise care.
This module represents the latest addition to the new patient-centric standard pioneered by Seegnal, increasing efficacy, expanding functionality, and increasing patient safety, which is replacing the current Drug to Drug Interaction standard, proven to be ineffective as published in the US National Library of Medicine study titled "Cost of Prescription Drug-Related Morbidity and Mortality" and located online here.
Mr. Schneid added, "This module will further differentiate and distinguish Seegnal from its legacy competitors, providing unmatched, yet much-needed clinical value. This module will directly save money to healthcare organizations by decreasing the number of Emergency Care, hospitalization and re-visits, decrease clinicians burn-out and improve patient quality of living."
About Seegnal
Seegnal is a public company that aims to solve one of the top causes of death and injuries in the modern world - Adverse Drug Effects (ADEs). Seegnal's Clinical Decision Support system introduces a paradigm shift in the approach to this problem by implementing a new elevated Patient-Centric Standard. Seegnal's SaaS technology exclusively integrates at the point-of-care, unique patient-specific data like genetics, results of lab tests, ECG, smoking, allergies, food, gender, age, and the effects of many concomitant medications, while reducing the current alert load for clinicians by over 90%. In practice, clinicians using Seegnal eHealth complete their prescription workflow with limited interruption, saving time and fatigue. Similarly, patients enjoy more tailored medication and improved safety, leading to better quality of life, due to the precision of alerts with up to 98% accuracy. Institutions reported a reduction in admissions, medication consumption, and ample time savings in prescription renewals. Seegnal eHealth is marketing its SaaS-based platform in the State of Israel (where recently the Ministry of Health has adopted Seegnal's patient-specific standard as the new standard in governmental hospitals), the UAE, the United Kingdom, the United States, and Poland. The platform is currently a "standard of care" system for over 10,000 clinicians in Israel, used on a daily basis for prescribing medications to their patients.
See www.seegnal.com.
Seegnal Media Contact:
Eyal Schneid
Chief Executive Officer
press@seegnal.com
+972-54-477-0558
www.seegnal.com
Cautionary Note Regarding Forward-Looking Information
This press release contains "forward-looking information" or "forward-looking statements" within the meaning of Canadian securities legislation. All statements included herein, other than statements of historical fact, including statements included in the "About Seegnal" section of this press release, are forward-looking. Generally, the forward-looking information and forward-looking statements can be identified by the use of forward-looking terminology such as "anticipate", "believes", "estimates", "expects", "intends", "may", "should", "will" or variations of such words or similar expressions. More particularly, and without limitation, this press release contains forward-looking information or forward-looking statements concerning the anticipated time to market of the new software module product offering. Seegnal cautions that all forward-looking information and forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of Seegnal, including expectations and assumptions concerning Seegnal and its products as well as other risks and uncertainties, including those described in Seegnal's filings available on SEDAR+ at www.sedarplus.ca. The reader is cautioned that assumptions used in the preparation of any forward-looking information or forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of Seegnal. The reader is cautioned not to place undue reliance on any forward-looking information or forward-looking statements. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking information and forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Seegnal does not undertake any obligation to update publicly or to revise any of the included forward-looking information or forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
The securities have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271384
SOURCE: Seegnal Inc.